// App-Quantinova.ai

P449 : Selective depletion of LAG3+ cells in T-cell-driven inflammation: a randomised, double-blind, placebo-controlled, FTIH phase I/Ib clinical trial

Researchers

Presenter

  • J Ellis

Principal Investigators

  • C Barrett

  • T Hopkins

  • A Richards

  • R Fuhr

  • M Albayaty

  • M Coenen

  • L Liefaard

  • K Leavens

  • K Nevin

  • S Tang

  • S Hughes

  • N Srinivasan

  • K Edwards

  • R Anselm

  • T Schmidt

  • J Stone

  • C Savage

  • N Wisniacki

  • R Tarzi

Medical Centers

  • GlaxoSmithKline, Clinical Pharmacology and Experimental Medicine, Stevenage, United Kingdom

  • PAREXEL International, Berlin, Germany

  • PAREXEL International, London, UK

  • Institute of Clinical Chemistry and Clinical Pharmacology, Study Center Bonn (SZB), Bonn, Germany

  • Glaxo Smith Kline, Stevenage, UK

  • GlaxoSmithKline, Upper Providence, PA

  • TxCell S.A., Valbonne, France

  • IMED Biotech, AstraZeneca, Cambridge, UK

Locations

  • United Kingdom

  • Germany

  • United States

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Autoimmune (AI)

Disease

  • Psoriasis

Biomarkers

  • Cluster of Differentiation 2AP

Drug/Treatment

  • GSK 2831781

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Pharmacokinetics

  • Double Blind/Blinded

  • Controlled

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved